학술논문
Recommendations for Hepatitis B Immunoglobulin and Antiviral Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation
Document Type
Report
Author
Akarsu, Mesut; Onem, Soner; Turan, Ilker; Adali, Gupse; Akdogan, Meral; Akyildiz, Murat; Aladag, Murat; Balaban, Yasemin; Danis, Nilay; Dayangac, Murat; Gencdal, Genco; Gokcan, Hale; Sertesen, Elif; Gurakar, Merve; Harputluoglu, Murat; Kabacam, Gokhan; Karademir, Sedat; Kiyici, Murat; Idilman, Ramazan; Karasu, Zeki
Source
The Turkish Journal of Gastroenterology. September 2021, Vol. 32 Issue 9, p712, 8 p.
Subject
Language
English
ISSN
1300-4948
Abstract
INTRODUCTION Hepatitis B virus (HBV) infection is one of the most important causes of chronic liver disease and remains a major cause of liver-related morbidity and mortality worldwide. (1) In [...]
The combination of hepatitis B immunoglobulin and potent nucleos(t)ide analogs after liver transplantation is considered as the standard of care for prophylaxis against hepatitis B virus recurrence. However, the recommended doses, route of administration, and duration of HBIG administration remain unclear. Moreover, hepatitis B immunoglobulin-free prophylaxis with potent nucleos(t)ide analogs has shown promising disease outcomes in preventing hepatitis B virus recurrence. The current recommendations, produced by the Turkish Association for the Study of the Liver, Acute Liver Failure and Liver Transplantation Special Interest Group, suggest a reduced need for hepatitis B immunoglobulin administration with effective long-term suppression of hepatitis B virus replication using potent nucleos(t) ide analogs after liver transplantation. Keywords: Hepatitis B, liver transplantation, recurrence
The combination of hepatitis B immunoglobulin and potent nucleos(t)ide analogs after liver transplantation is considered as the standard of care for prophylaxis against hepatitis B virus recurrence. However, the recommended doses, route of administration, and duration of HBIG administration remain unclear. Moreover, hepatitis B immunoglobulin-free prophylaxis with potent nucleos(t)ide analogs has shown promising disease outcomes in preventing hepatitis B virus recurrence. The current recommendations, produced by the Turkish Association for the Study of the Liver, Acute Liver Failure and Liver Transplantation Special Interest Group, suggest a reduced need for hepatitis B immunoglobulin administration with effective long-term suppression of hepatitis B virus replication using potent nucleos(t) ide analogs after liver transplantation. Keywords: Hepatitis B, liver transplantation, recurrence